The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•24 February 2026•

1 min read

Novo Nordisk's UBT251 Shows 19.7% Weight Loss in China Phase 2 Trial

Key Facts

1Novo Nordisk's UBT251 drug achieved a mean weight loss of 19.7% after 24 weeks in a trial.

2The drug is a triple agonist targeting GLP-1, GIP, and glucagon receptors, jointly developed with United Biotechnology.

3 months ago

Version History

Version 13 months ago

What changed: Updated the story to specify the Phase 2 trial status in China with partner TUL, and confirmed the drug's safety profile is consistent with existing incretin-based therapies.

Novo Nordisk and its partner, The United Laboratories International Holdings Limited (TUL), announced positive Phase 2 trial results for the experimental obesity drug UBT251. The study was conducted in China, specifically targeting Chinese participants living with overweight or obesity. Clinical data demonstrated a mean weight loss of 19.7% over a 24-week period using a triple agonist approach targeting GLP-1, GIP, and glucagon receptors. Importantly, the drug exhibited a well-tolerated safety profile, consistent with established incretin-based therapies currently on the market. These findings solidify Novo Nordisk's leadership in the competitive global weight-loss sector and highlight the potential of multi-receptor treatments. Analysts suggest the successful trial in the Chinese market serves as a significant catalyst for the company's long-term valuation and innovation strategy.